3.9 Article

Management of chronic heart failure in general practice in Australia

期刊

AUSTRALIAN FAMILY PHYSICIAN
卷 45, 期 11, 页码 823-827

出版社

ROYAL AUSTRALIAN COLLEGE GENERAL PRACTITIONERS

关键词

-

资金

  1. Australian Government Department of Health and Ageing
  2. Department of Veterans' Affairs
  3. AstraZeneca Pty Ltd (Australia)
  4. Merck, Sharp and Dohme (Australia) Pty Ltd
  5. Pfizer Australia Pty Ltd
  6. Sanofi-Aventis Australia Pty Ltd
  7. Novartis Pharmaceuticals Australia Pty Ltd
  8. GlaxoSmithKline Australia Pty Ltd
  9. Seqirus (Australia) Pty Ltd (bioCSL (Australia) Pty Ltd)
  10. Bayer Australia Ltd
  11. AbbVie Pty Ltd.

向作者/读者索取更多资源

Background Chronic heart failure is a common clinical syndrome associated with high healthcare system use. Objectives The aim of this study was to explore the management of chronic heart failure in Australian general practice. Methods Data from the Bettering the Evaluation and Care of Health program were used to determine the prevalence of chronic heart failure, use of natriuretic peptide testing, prescribing patterns, hospitalisation rates and referrals to community-based heart failure management programs in three study periods between 2010 and 2015. Results Data on 8989 patients from 308 general practitioners were analysed. Of these patients, 324 had chronic heart failure (prevalence 3.6%; 95% confidence interval [CI]: 3.1-4.2), 44% (95% CI: 34.5-53.6) of whom had been hospitalised for the condition. The mean number of prescribed heart failure medication agents was 2.26 (95% CI: 2.13-2.39) per patient. Discharge under community heart failure programs was not routine. Discussion Chronic heart failure is a significant burden in general practice. Strategies to optimise management and avoid hospitalisation, where possible, are needed.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

3.9
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据